CR9072A - 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica - Google Patents

4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica

Info

Publication number
CR9072A
CR9072A CR9072A CR9072A CR9072A CR 9072 A CR9072 A CR 9072A CR 9072 A CR9072 A CR 9072A CR 9072 A CR9072 A CR 9072A CR 9072 A CR9072 A CR 9072A
Authority
CR
Costa Rica
Prior art keywords
injury
quinolinocarbonitrilos
etinil
metoxifenil
dicloro
Prior art date
Application number
CR9072A
Other languages
English (en)
Inventor
Harris Boschelli Diane
Zaleska Margaret
Carolina Barrios-Sosa Ana
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9072A publication Critical patent/CR9072A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invencion se relaciona con compuestos de la formula, en donde R es metilo o etilo, R y R son independientemente alquilo de 1 a 3 atomos de carbono, o R y R, tomados juntos con el nitrogeno al cual ellos estan unidos, pueden formar un anillo de saturado 5 o 6 miembros el cual puede contener opcionalmente un heteroatomo adicioanl seleccionado de NR, O o S (O) n, n es 0-2, y R es hidrogeno o alquilo de 1 a 3 atomos de carbono, y sales farmaceuticamente aceptables de estos, y su uso para inhibir permeabilidad vascular causada por enfermedad lesion u otro trauma.
CR9072A 2004-10-22 2007-04-20 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica CR9072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
CR9072A true CR9072A (es) 2007-09-07

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9072A CR9072A (es) 2004-10-22 2007-04-20 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica

Country Status (24)

Country Link
US (1) US20060116375A1 (es)
EP (1) EP1802581B1 (es)
JP (1) JP2008517924A (es)
KR (1) KR20070085413A (es)
CN (1) CN101044117A (es)
AT (1) ATE391122T1 (es)
AU (1) AU2005299822A1 (es)
BR (1) BRPI0516995A (es)
CA (1) CA2581807A1 (es)
CR (1) CR9072A (es)
DE (1) DE602005005843T2 (es)
DK (1) DK1802581T3 (es)
EC (1) ECSP077385A (es)
ES (1) ES2303287T3 (es)
HK (1) HK1104555A1 (es)
IL (1) IL182547A0 (es)
MX (1) MX2007004833A (es)
NO (1) NO20071708L (es)
PL (1) PL1802581T3 (es)
PT (1) PT1802581E (es)
RU (1) RU2007111704A (es)
SI (1) SI1802581T1 (es)
WO (1) WO2006047262A1 (es)
ZA (1) ZA200703275B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
CN103848785B (zh) * 2012-12-04 2016-07-13 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
CA2581807A1 (en) 2006-05-04
IL182547A0 (en) 2007-09-20
CN101044117A (zh) 2007-09-26
EP1802581B1 (en) 2008-04-02
AU2005299822A1 (en) 2006-05-04
ECSP077385A (es) 2007-05-30
SI1802581T1 (sl) 2008-08-31
RU2007111704A (ru) 2008-11-27
ZA200703275B (en) 2008-08-27
DE602005005843T2 (de) 2009-05-14
JP2008517924A (ja) 2008-05-29
WO2006047262A1 (en) 2006-05-04
EP1802581A1 (en) 2007-07-04
PT1802581E (pt) 2008-06-03
MX2007004833A (es) 2007-05-16
DE602005005843D1 (de) 2008-05-15
DK1802581T3 (da) 2008-06-30
ES2303287T3 (es) 2008-08-01
HK1104555A1 (en) 2008-01-18
KR20070085413A (ko) 2007-08-27
US20060116375A1 (en) 2006-06-01
PL1802581T3 (pl) 2008-09-30
ATE391122T1 (de) 2008-04-15
NO20071708L (no) 2007-07-13
BRPI0516995A (pt) 2008-09-30

Similar Documents

Publication Publication Date Title
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
ECSP055935A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
DOP2006000243A (es) Derivados de pirazina
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
CR9072A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesion isquemica
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
ECSP003410A (es) Procedimientos e intermedios para preparar compuestos anticancerosos
UY28104A1 (es) Aminoalcoxiindoles

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)